Thomas Powles, MD, PhD, on Clinical Implications of the NORSE Trial: Erdafitinib Plus Cetrelimab in FGFR-Altered Advanced Urothelial Carcinoma

Posted: Wednesday, October 13, 2021

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses practical clinical issues raised by the NORSE study of patients with first-line metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations who received the kinase inhibitor erdafitinib plus the monoclonal antibody cetrelimab. A small percentage of patients with this disease are ineligible to receive cisplatin as first-line treatment due to FGFR alterations.